Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "gene- therapy" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-37 z 37
    Tytuł:
    Antiangiogenic gene therapy in inhibition of metastasis.
    Autorzy:
    Szala, Stanisław
    Szary, Jarosław
    Cichoń, Tomasz
    Sochanik, Aleksander
    Powiązania:
    https://bibliotekanauki.pl/articles/1043756.pdf
    Data publikacji:
    2002
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    antiangiogenic gene therapy
    encapsulation
    inducible gene expression
    metastasis
    Opis:
    This short review attempts to demonstrate the usefulness of antiangiogenic gene therapy in achieving inhibition of growth in experimentally-induced metastases. Certain normal tissues (for example skeletal muscle) may be used in vivo, after genetic modification, as a "bioreactor", able to produce and secrete into the bloodstream proteins known to exert antiangiogenic effects. By inhibiting neoangiogenesis these proteins would thus prevent the development of metastases. The review discusses also the perspectives of antimetastatic therapy based on certain types of allogenic cells (for example myoblasts and fibroblasts) that had been genetically modified and then microencapsulated. The strategy of encapsulation is aimed at protecting the modified cells secreting antiangiogenic factors from being eliminated by the immune system. Secretion of antiangiogenic proteins by these microencapsulated cells can be controlled with inducible promoters. Antiangiogenic genes remaining under the transcriptional control of such promoters may be switched on and off using antibiotics, such as tetracycline derivatives, or steroid hormones.
    Źródło:
    Acta Biochimica Polonica; 2002, 49, 2; 313-321
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Helper-dependent adenoviral vectors in experimental gene therapy
    Autorzy:
    Józkowicz, Alicja
    Dulak, Józef
    Powiązania:
    https://bibliotekanauki.pl/articles/1041362.pdf
    Data publikacji:
    2005
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    helper-dependent adenoviral vectors
    adenoviruses
    gene therapy
    Opis:
    In the majority of potential applications gene therapy will require an effective transfer of a transgene in vivo resulting in high-level and long-term transgene expression, all in the absence of significant toxicity or inflammatory responses. The most efficient vehicles for delivery of foreign genes to the target tissues are modified adenoviruses. Adenoviral vectors of the first generation, despite the high infection efficacy, have an essential drawback: they induce strong immune response, which leads to short term expression of the transgene, and limits their usefulness in clinical trials. In contrast, helper-dependent adenoviral vectors (HdAd) lacking all viral coding sequences display only minimal immunogenicity and negligible side-effects, allowing for long-term transgene expression. Thus, HdAd vehicles have become the carrier of choice for adenoviral vector-mediated experimental gene therapy, effectively used in animal models for delivery of transgenes into the liver, skeletal muscle, myocardium or brain. Strong and long-lasting expression of therapeutic genes has allowed for successful treatment of dyslipidemias, muscular dystrophy, obesity, hemophilia, and diabetes. Additionally, the large cloning capacity of HdAd, up to 37 kb, facilitates the use of physiologically regulated, endogenous promoters, instead of artificial viral promoter sequences. This enables also generation of the single vectors expressing multiple genes, which can be potentially useful for treatment of polygenic diseases. In this review we characterize the basic features of HdAd vectors and describe some of their experimental and potential clinical applications.
    Źródło:
    Acta Biochimica Polonica; 2005, 52, 3; 589-599
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Improved downstream process for the production of plasmid DNA for gene therapy
    Autorzy:
    Urthaler, Jochen
    Buchinger, Wolfgang
    Necina, Roman
    Powiązania:
    https://bibliotekanauki.pl/articles/1041381.pdf
    Data publikacji:
    2005
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    plasmid DNA
    production
    gene- therapy
    purification
    alkaline lysis
    chromatography
    Opis:
    Gene therapy and genetic vaccines promise to revolutionize the treatment of inherited and acquired diseases. Since viral vectors are generally associated with numerous disadvantages when applied to humans, the administration of naked DNA, or DNA packed into lipo- or polyplexes emerge as viable alternatives. To satisfy the increasing demand for pharmaceutical grade plasmids we developed a novel economic downstream process which overcomes the bottlenecks of common lab-scale techniques and meets all regulatory requirements. After cell lysis by an in-house developed gentle, automated continuous system the sequence of hydrophobic interaction, anion exchange and size exclusion chromatography guarantees the separation of impurities as well as undesired plasmid isoforms. After the consecutive chromatography steps, adjustment of concentration and final filtration are carried out. The final process was proven to be generally applicable and can be used from early clinical phases to market-supply. It is scaleable and free of animal-derived substances, detergents (except lysis) and organic solvents. The process delivers high-purity plasmid DNA of homogeneities up to 98% supercoiled form at a high yield in any desired final buffer.
    Źródło:
    Acta Biochimica Polonica; 2005, 52, 3; 703-711
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    IGF-I: from diagnostic to triple-helix gene therapy of solid tumors.
    Autorzy:
    Trojan, Ladislas
    Kopinski, Piotr
    Wei, Ming
    Ly, Adama
    Glogowska, Aleksandra
    Czarny, Jolanta
    Shevelev, Alexander
    Przewlocki, Ryszard
    Henin, Dominique
    Trojan, Jerzy
    Powiązania:
    https://bibliotekanauki.pl/articles/1043704.pdf
    Data publikacji:
    2002
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    glioblastoma
    tumors
    antisense
    triple-helix
    IGF-I
    gene therapy
    Opis:
    Alterations in the expression of growth factors and their receptors are associated with the growth and development of human tumors. One such growth factor is IGF-I (insulin-like growth factor I ), a 70-amino-acid polypeptide expressed in many tissues, including brain. IGF-I is also expressed at high levels in some nervous system-derived tumors, especially in glioblastoma. When using IGF-I as a diagnostic marker, 17 different tumors are considered as expressing the IGF-I gene. Malignant glioma, the most common human brain cancer, is usually fatal. Average survival is less than one year. Our strategy of gene therapy for the treatment of gliomas and other solid tumors is based on: 1) diagnostic using IGF-I gene expression as a differential marker, and 2) application of "triple-helix anti-IGF-I " therapy. In the latter approach, tumor cells are transfected with a vector, which encodes an oligoribonucleotide - an RNA strand containing oligopurine sequence which might be capable of forming a triple helix with an oligopurine and/or oligopyrimidine sequence of the promotor of IGF-I gene (RNA-IGF-I DNA triple helix). Human tumor cells transfected in vitro become down-regulated in the production of IGF-I and present immunogenic (MHC-I and B7 expression) and apoptotic characteristics. Similar results were obtained when IGF-I antisense strategy was applied. In both strategies the transfected cells reimplanted in vivo lose tumorigenicity and elicit tumor specific immunity which leads to elimination of established tumors.
    Źródło:
    Acta Biochimica Polonica; 2002, 49, 4; 979-990
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparaty siRNA w terapii genowej raka jajnika
    siRNA preparations in gene therapy of ovarian cancer
    Autorzy:
    Pankowska, Magdalena
    Stachurska, Anna
    Woźniak, Małgorzata
    Małecki, Maciej
    Powiązania:
    https://bibliotekanauki.pl/articles/1031566.pdf
    Data publikacji:
    2014
    Wydawca:
    Medical Communications
    Tematy:
    sirna
    rak jajnika
    terapia genowa
    badania kliniczne
    chemiooporność
    ovarian cancer
    gene therapy
    clinical research
    chemoresistance
    Opis:
    According to statistics, ovarian cancer is the fourth cause of death due to gynecologic cancer. It results from late diagnosis of the disease, caused by the lack of characteristic symptoms, as well as from unsatisfactory treatment methods due to e.g. cell resistance to chemotherapy. The search for new therapies is still in progress. It is believed that preparations whose activity is based on RNA interference, i.e. gene silencing with the use of siRNA, are a promising group of new antineoplastic medications. Fire et al. were awarded the Nobel Prize for discovering this phenomenon. The phenomenon of siRNA interference in healthy cells is a natural protective mechanism. Genes are silenced in the cytoplasm with the use of the Dicer enzyme. siRNA gene preparations are delivered into cells with the use of viral methods such as AAV or adenoviruses, as well as non-viral methods e.g. with the use of liposomes. Clinical trials concerning siRNA preparations are now in the first phase. They are conducted on two gene preparations: CALAA-01 and siRNA nanomolecule directed against PLK1. In this paper attention was drawn to the therapeutic meaning of siRNA sequences in relation to the following genes: MDR1, VEGF, MMP, CD44, HER2, SHH, STAT. Both experimental and clinical studies give hope for the use of the described mechanisms in fight with ovarian cancer in the future.
    Rak jajnika według statystyk zajmuje czwarte miejsce wśród zgonów z powodu nowotworów ginekologicznych. Wynika to zarówno z późnego rozpoznania choroby, spowodowanego brakiem charakterystycznych objawów, jak i stale niezadowalających efektów leczenia, m.in. ze względu na oporność komórek na chemioterapię. Poszukiwanie nowych metod terapii jest więc nadal aktualne. Uważa się, że obiecującą grupą potencjalnych leków przeciwnowotworowych mogą być preparaty, których aktywność opiera się na zjawisku interferencji RNA, czyli wyciszaniu genów za pomocą siRNA. Za odkrycie tego zjawiska Fire i wsp. zostali uhonorowani Nagrodą Nobla. Zjawisko interferencji siRNA w prawidłowych komórkach jest naturalnym mechanizmem obronnym. Do wyciszenia genów dochodzi w cytoplazmie przy udziale enzymu Dicer. Preparaty genowe siRNA wprowadza się do komórek, wykorzystując metody wirusowe, takie jak AAV czy adenowirusy, a także za pomocą metod niewirusowych, np. z zastosowaniem liposomów. Badania kliniczne preparatów genowych siRNA znajdują się obecnie w pierwszej fazie. Prowadzone są na dwóch preparatach genowych CALAA-01 oraz na nanocząsteczce siRNA skierowanej przeciw PLK1. W niniejszej pracy skupiono uwagę na terapeutycznym znaczeniu sekwencji siRNA w stosunku do genów: MDR1, VEGF, MMP, CD44, HER2, SHH, STAT. Zarówno badania eksperymentalne, jak i kliniczne niosą nadzieję na wykorzystanie w przyszłości omawianego mechanizmu do walki z rakiem jajnika.
    Źródło:
    Current Gynecologic Oncology; 2014, 12, 3; 197-205
    2451-0750
    Pojawia się w:
    Current Gynecologic Oncology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours
    Autorzy:
    Jazowiecka-Rakus, Joanna
    Jarosz, Magdalena
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1041289.pdf
    Data publikacji:
    2006
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    angiogenesis
    combination
    vasostatin
    cyclophosphamide
    gene therapy
    Opis:
    Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.
    Źródło:
    Acta Biochimica Polonica; 2006, 53, 1; 199-202
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo.
    Autorzy:
    Małecki;, Maciej
    Przybyszewska, Małgorzata
    Janik, Przemysław
    Powiązania:
    https://bibliotekanauki.pl/articles/1043468.pdf
    Data publikacji:
    2003
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    angiogenesis
    gene therapy
    bicistronic vectors
    Opis:
    Manipulation of angiogenesis in vivo is an example of successful gene therapy strategies. Overexpression of angiogenic genes like VEGF, FGF or PDGF causes new vessel formation and improves the clinical state of patients. Gene therapy is a very promising procedure but requires large amounts of pharmaceutical-grade plasmid DNA. In this regard we have constructed a bicistronic plasmid DNA vector encoding two proangiogenic factors, VEGF165 and FGF-2. The construct (pVIF) contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV) which permits both genes to be translated from a single bicistronic mRNA. The IRES sequence allows for a high efficiency of gene expression in vivo. The pVIF vector was characterized in vitro and in vivo. In vivo angiogenesis studies showed that the bicistronic vector encoding two proangiogenic factors induces the formation of new vessels significantly more than pVEGF165 or pFGF-2 alone. In our opinion the combined proangiogenic approach with VEGF165 and FGF-2 is more powerful and efficient than single gene therapy. We also postulate that IRES sequence can serve as a useful device improving efficiency of gene therapy.
    Źródło:
    Acta Biochimica Polonica; 2003, 50, 3; 875-882
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Charakterystyka nanostrukturalna materiału genetycznego do zastosowania w terapii genowej
    Nanostructural characteristics of genetic material for gene therapy application
    Autorzy:
    Duda, M.
    Frączkowska, K.
    Przybyło, M.
    Kopaczyńska, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/261139.pdf
    Data publikacji:
    2015
    Wydawca:
    Politechnika Wrocławska. Wydział Podstawowych Problemów Techniki. Katedra Inżynierii Biomedycznej
    Tematy:
    kondensacja DNA
    spermidyna
    terapia genowa
    mikroskopia sił atomowych
    DNA condensation
    spermidine
    gene therapy
    atomic force microscopy (AFM)
    Opis:
    Terapia genowa jest obecnie bardzo dynamicznie rozwijającą się techniką biomedyczną, która może znaleźć zastosowanie w medycynie w leczeniu chorób przewlekłych i dziedzicznych. Badania skupiają się na opracowywaniu nowych strategii dotyczących procesów kondensacji i ochrony materiału genetycznego (DNA) wprowadzanego do komórki docelowej. Struktura i stopień upakowania dostarczanego DNA wpływają na kluczowe właściwości fizykochemiczne, determinujące czy wprowadzony wektor rekombinowany ulegnie ekspresji, czy też degradacji. Związki chemiczne, zwane czynnikami kondensującymi, to substancje powodujące zwinięcie DNA, a stopień kondensacji materiału genetycznego zależy bezpośrednio od rodzaju i stężenia użytego czynnika kondensującego. Do cząsteczek wykazujących właściwości kondensujące należą poliaminy, w opisywanym eksperymencie zastosowano poliaminę – spermidynę. Przeprowadzone badania miały na celu charakterystykę nanostrukturalną materiału genetycznego pod wpływem działania czynnika kondensującego. W wyniku analizy wykonanej za pomocą mikroskopii sił atomowych (AFM) wykazano, że plazmid DNA ulega kondensacji pod wpływem spermidyny, formując struktury rozetowe.
    Gene therapy is a new promising method that may find many applications in modern biomedicine. Especially, it may be a powerful tool in chronic and hereditary diseases treatment. Current studies focus on development of novel strategies concerning genetic material (DNA) condensation and protection, whilst it is introduced into the cellular nucleus. Once the DNA enters the cell, it’s either passed on and expressed in the nucleus or degraded by intracellular nucleases. The structure and the degree of compaction influence physicochemical properties that determine what will happen to delivered genetic material. DNA coiling can be caused by chemical compounds called compaction agents, such as polyamines like spermidine used in this study. The aim of this research was to examine the nanostructural characteristics of genetic material exposed to compaction agent. The measurements and analysis performed by atomic force microscopy (AFM) indicate that DNA plasmid undergoes condensation and forms rosette-like structures once subjected to spermidine.
    Źródło:
    Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna; 2015, 21, 1; 1-8
    1234-5563
    Pojawia się w:
    Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Newest therapeutic options for adrenoleukodystrophy
    Autorzy:
    Gołębiowska, Maria
    Gołębiowska, Beata
    Beń-Skowronek, Iwona
    Powiązania:
    https://bibliotekanauki.pl/articles/1163988.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    X-ALD
    adrenoleukodystrophy
    gene therapy
    neurodegenerative disorders
    Opis:
    X-linked adrenoleukodystrophy is a genetic disease correlated with mutation of ATP-binding cassette, which results in errors of peroxisomal beta oxidation and accumulation of impaired very long chain fatty acids. This leads to degeneration of adrenal glands, spinal cord and myelin sheaths. Despite nearly 100 years of ALD history, the treatment is limited to few therapeutic options, mainly Lorenzo’s Oil and Hematopoetic stem cell transplant. Available therapy can only slow the progression of the disease in early stages. The aim of our study was to present the newest therapeutic options in X-ALD. Substantial articles on new treatment of X-ALD from period 2007-2018 in the Asian, European and American regions have been analyzed. Among 219 articles in PubMed Medline database related to therapy and treatment of X-ALD, 13 articles were selected for analysis, reviewed and divided into two main groups: cause-related treatment (11 articles) and symptoms-related treatment (2 articles). Within cause-related treatment, the usage of known medications such as eg. pioglitazone, natural phenols - resveratrol, gene therapy with adenoassociated virus serotype 9 or combined therapies (Hematopoetic Stem Cell Gene Therapy) have been reviewed. Symptoms related treatment attempted to reduce spasticity and secondary dystonia in X-ALD patients. Reviewed research presents progress in development of treatment options for X-ALD, however still in primary in vitro and animal tested stages. Secondary neurological symptoms medication is awaiting for better solutions for ALD patients, in order to improve their Quality of Life and allow symptomless course for a longer time.
    Źródło:
    World Scientific News; 2018, 108; 133-143
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice
    Autorzy:
    Mitrus, Iwona
    Delić, Klaudia
    Wróbel, Natalia
    Missol-Kolka, Ewa
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1041249.pdf
    Data publikacji:
    2006
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    antiangiogenic therapy
    interleukin-12 gene
    combined therapy
    Opis:
    We investigated suppression of murine B16(F10) melanoma tumor growth following a therapy which involved concomitant administration of cyclophosphamide and plasmid DNA bearing interleukin-12 gene. Since both therapeutic factors display antiangiogenic capabilities, we assumed that their use in blocking the formation of new blood vessels would result in augmented inhibition of tumor growth. This combined therapy regimen indeed resulted in a considerable suppression of tumor growth. We observed a statistically significant extension of treated animals' lifespan. Interestingly, the therapeutic effect was also obtained using a plasmid without an interleukin gene insert. This observation suggests that plasmid DNA, which has been widely applied for treating neoplastic tumors, contains element(s) that elicit immune response in mice.
    Źródło:
    Acta Biochimica Polonica; 2006, 53, 2; 357-360
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
    Autorzy:
    Jazowiecka-Rakus, Joanna
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1041570.pdf
    Data publikacji:
    2004
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    cancer gene therapy
    tumour targeting
    cytosine deaminase
    Salmonella
    Opis:
    A tumour therapy is proposed based on attenuated Salmonella typhimurium VNP20047 expressing the Escherichia coli cytosine deaminase gene. VNP20047 was administered intravenously to B16(F10) melanoma-bearing C57BL/6 mice. VNP20047 proliferated within tumours and livers regardless of the initial inoculum dose. After 10 days the number of bacteria increased in livers up to 4.2 × 106 cfu/g and decreased in tumours down to 5.9 × 106 cfu/g. VNP20047 at 1 × 105 cfu/mouse, when combined with 5-fluorocytosine, inhibited tumour growth by 85% without prolonging animal survival. Histology studies revealed severe lesions in tumours and livers. These data suggest that S. typhimurium VNP20047 induced inflammatory responses, even though the strain was attenuated.
    Źródło:
    Acta Biochimica Polonica; 2004, 51, 3; 851-856
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Direct transfer of IL-12 gene into growing Renca tumors.
    Autorzy:
    Budryk, Magdalena
    Wilczyńska, Urszula
    Szary, Jarosław
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1044365.pdf
    Data publikacji:
    2000
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    IL-12 gene
    tumor gene therapy
    naked DNA
    Opis:
    We investigated the feasibility of transferring naked plasmid DNA containing a therapeutic gene (IL-12) into mice harboring growing Renca tumors. We found that naked DNA transferred into growing Renca and B16(F10) tumors gives higher expression level of reporter gene than complexes of DNA with DDAB/ DOPE or DC-Chol/DOPE. Transfer of naked DNA carrying the IL-12 gene into growing Renca tumors causes a distinct therapeutic effect that depends on the time span between inoculation of mice with cancer cells and the beginning of the therapy. Therapy started on day 3 resulted in total cure (100%) of mice.
    Źródło:
    Acta Biochimica Polonica; 2000, 47, 2; 385-391
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer.
    Autorzy:
    Wilczyńska, Urszula
    Kucharska, Anna
    Szary, Jarosław
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1044050.pdf
    Data publikacji:
    2001
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    angiogenesis
    IL-12 gene
    tumor gene therapy
    angiostatin
    Opis:
    We investigated the feasibility of a novel therapeutic approach to treat neoplastic diseases in mice. This novel strategy consists in delivering a protein (angiostatin) with strong antiangiogenic properties, followed by administration of the interleukin 12 gene that is strongly immunomodulatory and has also some antiangiogenic effects. When angiostatin-mediated antiangiogenic therapy was used in combination with intratumor delivery of the IL-12 gene (a strategy much safer than IL-12 protein administration), this produced a synergistic therapeutic effect.
    Źródło:
    Acta Biochimica Polonica; 2001, 48, 4; 1077-1084
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cancer immunotherapy using cells modified with cytokine genes.
    Autorzy:
    Kowalczyk, Dariusz
    Wysocki, Piotr
    Mackiewicz, Andrzej
    Powiązania:
    https://bibliotekanauki.pl/articles/1043434.pdf
    Data publikacji:
    2003
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    cancer
    cancer vaccines
    cytokines
    dendritic cells
    gene therapy
    Opis:
    The ability of various cytokines to hamper tumor growth or to induce anti-tumor immune response has resulted in their study as antitumor agents in gene therapy approaches. In this review we will concentrate on the costimulation of antitumor immune responses using modification of various cell types by cytokine genes. Several strategies have emerged such as (i) modification of tumor cells with cytokine genes ex vivo (whole tumor cell vaccines), (ii) ex vivo modification of other cell types for cytokine gene delivery, (iii) delivery of cytokine genes into tumor microenvironment in vivo, (iv) modification of dendritic cells with cytokine genes ex vivo. Originally single cytokine genes were used. Subsequently, multiple cytokine genes were applied simultaneously, or in combination with other factors such as chemokines, membrane bound co-stimulatory molecules, or tumor associated antigens. In this review we discuss these strategies and their use in cancer treatment as well as the promises and limitations of cytokine based cancer gene therapy. Clinical trials, including our own experience, employing the above strategies are discussed.
    Źródło:
    Acta Biochimica Polonica; 2003, 50, 3; 613-624
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Adeno-associated virus vector-mediated gene delivery to the vasculature and kidney.
    Autorzy:
    Kapturczak, Matthias
    Chen, Sifeng
    Agarwal, Anupam
    Powiązania:
    https://bibliotekanauki.pl/articles/1041403.pdf
    Data publikacji:
    2005
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    kidney
    vasculature
    viral vectors
    endothelium
    recombinant adeno-associated virus
    gene therapy
    Opis:
    Relatively successful elsewhere, gene delivery aimed at the vasculature and kidney has made very little progress. In the kidney, the hurdles are related to the unique structure–function relationships of this organ and in the blood vessels to a variety of, mostly endothelial, factors making the delivery of transgenes very difficult. Among gene-therapeutic approaches, most viral gene delivery systems utilized to date have shown significant practical and safety-related limitations due to the level and duration of recombinant transgene expression as well as their induction of a significant host immune response to vector proteins. Recombinant adeno-associated virus (rAAV) vectors appear to offer a vehicle for safe, long-term transgene expression. rAAV-based vectors are characterized by a relative non-immunogenicity and the absence of viral coding sequences. Furthermore, they allow for establishment of long-term latency without deleterious effects on the host cell. This brief review addresses problems related to transgene-delivery to kidney and vasculature with particular attention given to rAAV vectors. The potential for gene therapy as a strategy for selected renal and vascular diseases is also discussed.
    Źródło:
    Acta Biochimica Polonica; 2005, 52, 2; 293-299
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    pVAX1 plasmid vector-mediated gene transfer of soluble TRAIL suppresses human hepatocellular carcinoma growth in nude mice
    Autorzy:
    Zhang, Yan
    Ma, Cun
    Liu, Hua
    Zhang, Xiu
    Sun, Wen
    Powiązania:
    https://bibliotekanauki.pl/articles/1041078.pdf
    Data publikacji:
    2007
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    pVAX1
    soluble TRAIL
    naked DNA
    gene therapy
    hepatocellular carcinoma
    Opis:
    The extracellular domain of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may function as a soluble cytokine to selectively kill various cancer cells without toxicity to most normal cells. We used a high-biosafety plasmid pVAX1 as a vector and constructed a recombinant plasmid expressing the extracellular domain (95-281 aa) of human TRAIL fused with signal peptides of human IgGγ, designated as pVAX-sT. Transduction of human BEL7402 liver cancer cells with pVAX-sT led to high levels of sTRAIL protein in the cell culture media and induced apoptosis. The therapeutic potential of pVAX-sT was then evaluated in the BEL7402 transplanted naked mouse model. Subsequent intratumoral administration of naked pVAX-sT resulted in the expression of soluble TRAIL in the sera and the tumor site, as well as effective suppression of tumor growth, with no toxicity to liver. In conclusion, the successful inhibition of liver cancer growth and the absence of detectable toxicity suggest that pVAX-sT could be useful in the gene therapy of liver cancer.
    Źródło:
    Acta Biochimica Polonica; 2007, 54, 2; 307-313
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The role of cell adhesion molecule in cancer progression and its application in cancer therapy.
    Autorzy:
    Okegawa, Takatsugu
    Pong, Rey-Chen
    Li, Yingming
    Hsieh, Jer-Tsong
    Powiązania:
    https://bibliotekanauki.pl/articles/1043281.pdf
    Data publikacji:
    2004
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    cancer gene therapy
    gene
    cell adhesion molecules
    tumor progression
    tumor suppressor
    Opis:
    Multiple and diverse cell adhesion molecules take part in intercellular and cell-extracellular matrix interactions of cancer. Cancer progression is a multi-step process in which some adhesion molecules play a pivotal role in the development of recurrent, invasive, and distant metastasis. A growing body of evidence indicates that alterations in the adhesion properties of neoplastic cells play a pivotal role in the development and progression of cancer. Loss of intercellular adhesion and the desquamation of cells from the underlying lamina propria allows malignant cells to escape from their site of origin, degrade the extracellular matrix, acquire a more motile and invasion phenotype, and finally, invade and metastasize. In addition to participating in tumor invasiveness and metastasis, adhesion molecules regulate or significantly contribute to a variety of functions including signal transduction, cell growth, differentiation, site-specific gene expression, morphogenesis, immunologic function, cell motility, wound healing, and inflammation. Cell adhesion molecule (CAM), a diverse system of transmembrane glycoproteins has been identified that mediates the cell-cell and cell-extracellular matrix adhesion and also serves as the receptor for different kinds of virus. We summarize recent progress regarding the role of CAM, particularly, immunoglobulin-CAMs and cadherins in the progression of cancer and discuss the potential application of CAMs in the development of cancer therapy mainly on urogenital cancer.
    Źródło:
    Acta Biochimica Polonica; 2004, 51, 2; 445-457
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Stem cells: applications, perspectives, misunderstandings
    Autorzy:
    Dulak, Józef
    Powiązania:
    https://bibliotekanauki.pl/articles/704245.pdf
    Data publikacji:
    2020
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    stem cells
    cellular therapies
    gene therapy
    embryonic stem cells
    induced pluripotent stem cells
    Opis:
    Stem cells exist and can do a lot. For several decades, bone marrow and umbilical cord blood transplants containing haematopoietic stem cells have been used in the treatment of blood diseases. Genetic modifications (gene therapy) of such cells help to cure complex immunodeficiencies and severe anaemias. The limbal stem cells taken from the eye and properly multiplied can regenerate the damaged cornea, and the epidermal stem cells help in the treatment of severe burns and some hereditary, severe skin diseases. Promising experimental research is under way on other uses of stem cells. However, these cells are appropriately selected, having real ability to differentiate into specialized cells whose malfunction is the cause of the disease. Therapeutic applications of stem cells are apparently limited to date. Meanwhile, the Internet is full of advertisements for supposedly miraculous treatments for almost any disease. Stem cells have become a modern synonym of the Holy Grail. A wonderful dish, transforming every drink into elixir of health, youth and long life. Stem cells from a single source, e.g., umbilical cord blood, or so-called cells, although without proven properties of stem cells, are offered in commercial private clinics as a panacea for autism, cerebral palsy, spina bifida, eye diseases, amyotrophic lateral sclerosis and dozens other disorders. Without justification for their action in these diseases, without convincing evidence of safety, but for a high fee. This article discusses stem cells and misunderstandings about including any cells among them. It draws attention to the real possibilities and confirmed uses of stem cells and presents the problems, doubts and dangers for patients associated with commercial offers of treatments using “stem” cells. The author cites the positions of scientific institutions and societies warning against premature commercialization of unjustified and potentially dangerous therapies
    Źródło:
    Nauka; 2020, 1
    1231-8515
    Pojawia się w:
    Nauka
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Inhibition and regression of atherosclerotic lesions.
    Autorzy:
    Oka, Kazuhiro
    Chan, Lawrence
    Powiązania:
    https://bibliotekanauki.pl/articles/1041405.pdf
    Data publikacji:
    2005
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    inflammation
    atherosclerosis
    helper-dependent adenovirus
    lesion regression
    inhibition of lesion progression
    gene therapy
    Opis:
    Atherosclerosis, once believed to be a result of a slow, irreversible process resulting from lipid accumulation in arterial walls, is now recognized as a dynamic process with reversibility. Liver-directed gene therapy for dyslipidemia aims to treat patients who are not responsive to currently available primary and secondary prevention. Moreover, gene therapy strategies have also proved valuable in studying the dynamics of atherosclerotic lesion formation, progression, and remodeling in experimental animals. Recent results on the long-term effect of gene therapy suggest that hepatic expression of therapeutic genes suppresses inflammation and has profound effects on the nature of the atherogenic process.
    Źródło:
    Acta Biochimica Polonica; 2005, 52, 2; 311-319
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Zastosowanie form liposomalnych substancji
    The use of liposomal forms of substances
    Autorzy:
    Słomczyńska, Patrycja
    Paradowska, Katarzyna
    Powiązania:
    https://bibliotekanauki.pl/articles/31339065.pdf
    Data publikacji:
    2024-05-02
    Wydawca:
    Wydawnictwo Naukowe Medyk sp. z o.o.
    Tematy:
    liposome
    drug delivery system
    gene therapy
    cosmetics
    liposom
    nośniki substancji leczniczych
    terapia genowa
    kosmetyki
    Opis:
    Liposomes are used as carriers of active compounds in various industries, such as pharmaceuticals, cosmetics, and food. Liposomal delivery systems of active substances play a significant role in the design of therapeutic formulations to improve therapeutic agents. The main goals of using preparations in liposomal form are to reduce toxicity and increase accumulation at the target site. This method of administering the active substance ensures greater safety and effectiveness of drug delivery, particularly with antiviral, antifungal, and antimicrobial properties. Liposomes can be used in gene therapy to precisely administer lower concentrations of medicinal substances to cells compared to non-liposomal counterparts. Liposomes have various applications in immunology, dermatology, and cancer therapy. Specifically, in cosmetology, innovative anti-aging, vitamin, and regenerating products for the deep layers of the epidermis can be developed using these structures. This article provides a brief overview of the structure and types of liposomes, which have great potential as carriers of active substances in medicinal and cosmetic products. The discussion included examples of the use of liposomes in medicine, such as anti-cancer, anti-psoriatic therapy, and anesthesiology. Additionally, the use of liposomes in cosmetology was discussed, specifically in products with anti-aging and antioxidant properties.
    Liposomy jako nośniki aktywnych związków znalazły zastosowanie w kilku gałęziach przemysłu, m.in. farmaceutycznym, kosmetycznym czy spożywczym. Liposomowe systemy dostarczania substancji aktywnych pełnią znaczącą rolę w projektowaniu preparatów leczniczych w celu ich ulepszenia. Zmniejszenie toksyczności i zwiększenie akumulacji w miejscu docelowym to główne cele zastosowania preparatów w formie liposomalnej. Taka forma podawania substancji czynnej zapewnia większe bezpieczeństwo i skuteczność podawania leków, m.in. o działaniu przeciwwirusowym, przeciwgrzybiczym czy przeciwdrobnoustrojowym. Możliwości wykorzystania liposomów w terapii genowej pozwalają na precyzyjne podanie do komórek mniejszych stężeń substancji leczniczych w porównaniu do ich nieliposomalnych odpowiedników. Obecne zastosowania liposomów obejmują immunologię, dermatologię i terapię nowotworów. W kosmetologii stanowią innowacyjne produkty przeciwstarzeniowe, witaminowe oraz regenerujące głębokie warstwy naskórka. W artykule przedstawiono krótką charakterystykę budowy i rodzajów poznanych liposomów, które wykazują duży potencjał zastosowania tych struktur jako nośników substancji aktywnych w produktach leczniczych i kosmetycznych. Omówiono także przykłady zastosowań liposomów w medycynie w terapii przeciwnowotworowej, przeciwłuszczycowej czy anestezjologii oraz w kosmetologii w produktach o działaniu anti-ageing i antyoksydacyjnym.
    Źródło:
    Lek w Polsce; 2024, 394, 3; 39-47
    2353-8597
    Pojawia się w:
    Lek w Polsce
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Targeting site-specific chromosome integration.
    Autorzy:
    Nuno-Gonzalez, Patricia
    Chao, Hsu
    Oka, Kazuhiro
    Powiązania:
    https://bibliotekanauki.pl/articles/1041401.pdf
    Data publikacji:
    2005
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    adeno-associated virus
    phage C31 integrase
    helper-dependent adenovirus
    hybrid vector
    viral vector
    gene therapy
    Opis:
    The concept of gene therapy was introduced with great promise and high expectations. However, what appeared simple in theory has not translated into practice. Despite some success in clinical trials, the research community is still facing an old problem: namely, the need for a vector that can deliver a gene to target cells without adverse events while maintaining a long-term therapeutic effect. Some of these challenges are being addressed by the development of hybrid vectors which meld two different viral systems to incorporate efficient gene delivery and large cloning capacity with site-specific integration. The two known systems that integrate genes into specific sites in mammalian genomes are the adeno-associated virus and phage integrases. Recent experiments with hybrid vectors incorporating both of these systems are encouraging. However, extensive research should be directed towards the safety and efficacy of this approach before it will be available for gene therapy.
    Źródło:
    Acta Biochimica Polonica; 2005, 52, 2; 285-291
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Use of HIV as a gene transfer vector
    Autorzy:
    Pluta, Krzysztof
    Kacprzak, Magdalena
    Powiązania:
    https://bibliotekanauki.pl/articles/1040467.pdf
    Data publikacji:
    2009
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    Lentivirus
    lentiviral vectors
    AIDS
    HIV-1 life cycle
    viral-host protein interactions
    gene therapy
    animal transgenesis
    cell engineering
    Opis:
    Despite the extensive research efforts over the past 25 years that have focused on HIV, there is still no cure for AIDS. However, tremendous progress in the understanding of the structure and biology of the HIV virus led to the development of safe and potent HIV-based transgene delivery vectors. These genetic vehicles are referred to as lentiviral vectors. They appear to be better suited for particular applications, such as transgene delivery into stem cells, compared to other viral- and non-viral vectors. This is because Lentivirus-based vectors can efficiently infect nondividing and slowly dividing cells. In the present review article, the current state of understanding of HIV-1 is discussed and the main characteristics that had an impact on vector design are outlined. A historical view on the vector concept is presented to facilitate discussion of recent results in vector engineering in a broader context. Subsequently, a state of the art overview concerning vector construction and vector production is given. This review also touches upon the subject of lentiviral vector safety and related topics that can be helpful in addressing this issue are discussed. Finally, examples of Lentivirus-based gene delivery systems and their applications are presented, with emphasis on animal transgenesis and human gene therapy.
    Źródło:
    Acta Biochimica Polonica; 2009, 56, 4; 531-595
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Glaucoma - new possibilities, new research
    Jaskra – nowe możliwości, nowe badania
    Autorzy:
    Szumny, Dorota
    Mulak, Małgorzata
    Powiązania:
    https://bibliotekanauki.pl/articles/4172992.pdf
    Data publikacji:
    2023-03-31
    Wydawca:
    Medical Education
    Tematy:
    glaucoma
    treatment
    new drugs
    new therapies
    neuroprotection
    gene therapy
    jaskra
    leczenie
    nowe leki
    nowe terapie
    neuroprotekcja
    terapia genowa
    Opis:
    Research efforts to develop effective and safe antiglaucoma drugs have been ongoing for many years. The cornerstone of treatment is still baroprotection, as this is virtually the only method available to protect the optic nerve and slow glaucoma progression, which can be easily controlled by an ophthalmologist. Research is also being conducted in the direction of neuroprotection, where new compounds are being evaluated, as well as those that have been used for years as adjunctive treatments. The greatest hope lies in gene therapy, which still has many problems to be solved, but it is the only one that offers hope for the patient’s complete recovery.
    Od wielu lat trwają prace badawcze nad opracowaniem skutecznych i bezpiecznych leków przeciwjaskrowych. Podstawę leczenia stanowi ciągle baroprotekcja, ponieważ jest to praktycznie jedyna dostępna metoda umożliwiająca ochronę nerwu wzrokowego i spowolnienie progresji, jaka może być łatwo kontrolowana przez lekarza okulistę. Badania prowadzone są również w kierunku neuroprotekcji; ocenia się w nich związki zarówno nowe, jak i te, które od lat są już stosowane w ramach leczenia wspomagającego. Największe nadzieje wzbudza terapia genowa, wiąże się z nią jednak jeszcze wiele problemów do rozwiązania, ale tylko ona może umożliwić całkowite wyleczenie.
    Źródło:
    OphthaTherapy; 2023, 10, 1; 7-11
    2353-7175
    2543-9987
    Pojawia się w:
    OphthaTherapy
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Molekularne podłoże i terapia rdzeniowego zaniku mięśni
    Molecular basis and therapy of spinal muscular atrophy
    Autorzy:
    Szczerba, Anna
    Śliwa, Aleksandra
    Żarowski, Marcin
    Jankowska, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/2045802.pdf
    Data publikacji:
    2018
    Wydawca:
    Polskie Towarzystwo Neurologów Dziecięcych
    Tematy:
    rdzeniowy zanik mięśni
    gen SMN
    białko SMN
    antysensowe oligonukleotydy
    nusinersen
    terapia genowa
    AVXS
    spinal muscular atrophy
    SMN gene
    SMN protein
    antisense oligonucleotides Spinraza
    gene therapy
    Zolgensma
    Opis:
    Rdzeniowy zanik mięśni, SMA (spinal muscular atrophy) to genetyczna choroba powodowana mutacją genu SMN1 i w konsekwencji niedoborem białka SMN (survival of motor neuron), które odgrywa kluczową rolę w regulacji ekspresji genów w motoneuronach. Jego brak prowadzi do zwyrodnienia i apoptozy komórek rogów przednich rdzenia kręgowego i w konsekwencji zaniku mięśni. Gen SMN w ludzkim genomie występuje w co najmniej dwóch kopiach: SMN1 i SMN2. Oba geny kodują identyczne białko, jednak transkrypty SMN1 mają pełną długość (FL-SMN), a 90% transkryptów SMN2 jest pozbawiona eksonu 7 (SMN-Δ7), co powoduje niefunkcjonalność białka. FL-SMN jest niezbędne do prawidłowego przeprowadzenia procesu splicingu. Niskie stężenie białka SMN upośledza także dynamikę szkieletu aktynowego, co skutkuje zahamowaniem wzrostu aksonów motoneuronów. Dotychczasowe leczenie SMA opierało się głównie na działaniach neuroprotekcyjnych i wzmacniających siłę mięśni. Obecnie, dzięki wykorzystaniu antysensowych nukleotydów (ASO), możliwa jest terapia modulująca przebieg splicingu, która pozwala na włączenie eksonu 7 do transkryptu SMN2. Takim ASO jest nusinersen, który został zatwierdzony do użytku w USA i Europie; jest on w pełni refundowany w Polsce. Terapeutyk jest przeznaczony do leczenia pacjentów ze wszystkimi typami SMA w każdym wieku. Inną strategią leczenia jest terapia genowa pod nazwą onasemnogene abeparvovec (AVXS-101), polegająca na wprowadzeniu do organizmu pacjenta prawidłowej kopii genu SMN1. Nośnikiem genu terapeutycznego, wnikającego jedynie do komórek układu nerwowego, jest wektor wirusowy AAV. Lek ten został zatwierdzony przez FDA w leczeniu SMA pacjentów poniżej 2. roku życia.
    Spinal muscular atrophy (SMA) is a genetic disorder caused by mutations in the SMN1 gene and, consequently, a deficiency of the SMN (survival of motor neuron) protein, which plays a key role in regulating gene expression in motoneurons. Its absence leads to degeneration and apoptosis of the anterior horn cells of the spinal cord and, as a consequence, to muscular atrophy. In the human genome the SMN gene is found in at least two copies: SMN1 and SMN2. Both genes encode the same protein, however, SMN1 transcripts are full-length (FL-SMN) and 90% of SMN2 transcripts are deprived of exon 7 (SMN-Δ7), which causes the protein to be non-functional. FL-SMN is necessary for proper splicing process. Low concentration of the SMN protein also impairs the dynamics of the actin skeleton, which results in inhibition of motoneuron axon growth. Hitherto SMA treatment was based mainly on neuroprotective and muscle strength enhancing approaches. Currently, thanks to the use of antisense nucleotides (ASO), it is possible to modulate the splicing process of SMN2, which allows the incorporation of exon 7 into the SMN2 transcripts. Nusinersen is an ASO that has been approved for clinical use in USA and Europe; it is fully refunded in Poland. The therapy is intended for the treatment of patients with all types of SMA at all ages. Another treatment strategy is the gene therapy called onasemnogene abeparvovec (AVXS-101) which allows introducing the correct copy of the SMN1 gene into the patient’s body. The carrier of the therapeutic gene that enters only the cells of the nervous system is an AAV viral vector. This drug has been approved by the FDA for the treatment of SMA in patients under 2 years of age.
    Źródło:
    Neurologia Dziecięca; 2018, 27, 55; 39-46
    1230-3690
    2451-1897
    Pojawia się w:
    Neurologia Dziecięca
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Isophosphoramide mustard analogues as prodrugs for anti-cancer gene-directed enzyme-prodrug therapy (GDEPT).
    Autorzy:
    Misiura, Konrad
    Szymanowicz, Daria
    Kuśnierczyk, Halina
    Wietrzyk, Joanna
    Opolski, Adam
    Powiązania:
    https://bibliotekanauki.pl/articles/1043823.pdf
    Data publikacji:
    2002
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    prodrugs
    GDEPT
    ifosfamide
    isophosphoramide mustard
    antitumour treatment
    Opis:
    Two types of prodrugs, benzyl analogues of isophosphoramide mustard (iPAM), activated by cytochrome P450, and acylthioethyl analogues, activated by esterases, were designed. In contrast to iPAM that hydrolyse rapidly, the examined compounds are stable in phosphate-buffered saline and Tris buffer. Benzyl analogues of iPAM are poor substrates for cytochrome P450, are not cytotoxic and posses no antitumour activity. Acylthioethyl analogues of iPAM are good substrates for pig liver esterase, are cytotoxic and exert antitumour activity against L1210 leukaemia in mice. The observed correlation for iPAM analogues between their susceptibility to hydrolysis and cytotoxicity and antitumour activity suggests possible application of these compounds as the prodrugs in gene-directed enzyme-prodrug therapy.
    Źródło:
    Acta Biochimica Polonica; 2002, 49, 1; 169-176
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter.
    Autorzy:
    Dąbrowska, Anna
    Szary, Jarosław
    Kowalczuk, Małgorzata
    Szala, Stanisław
    Ugorski, Maciej
    Powiązania:
    https://bibliotekanauki.pl/articles/1041550.pdf
    Data publikacji:
    2004
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    CEA promoter
    E. coli cytosine deaminase
    gene-directed enzyme prodrug therapy
    Opis:
    Recent studies have suggested that carcinoembryonic antigen (CEA)-promoter sequences are active only in CEA-positive cells, filing in the criteria for tumor specific targeting of suicide genes. However, the present study on gene therapy of colon cancer and cell-specificity of CEA promoter, provide evidence that CEA-positive and CEA-negative cells transfected with E. coli cytosine deaminase (CD) gene under the control of CEA promotor sequence are sensitive to enzyme/pro-drug therapy with 5-fluorocytosine (5-FC). Individual clones derived from the CEA-negative cell lines: melanoma Hs294T and glioblastoma T98G after transfection with CD differed profoundly in their sensitivity to 5-FC. The IC50 values for several clones of the CEA-negative cells were almost the same as for CEA-positive colon cancer cells. Such 5-FC-sensitive clones derived from the population of CEA-negative cells, present even in small number, because of the very effective bystender effect of this enzyme/pro-drug system can cause severe problems during therapy by efficiently killing surrounding normal cells. Safety is the major issue in gene therapy. Our data suggest that the safety of gene-directed enzyme pro-drug therapy (GDEPT) with CEA promoter driven expression of therapeutic genes is not so obvious as it has originally been claimed.
    Źródło:
    Acta Biochimica Polonica; 2004, 51, 3; 723-732
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The interplay between stochastic gene switching and certain metronomics therapies.
    Autorzy:
    Puszynski, Krzysztof
    Powiązania:
    https://bibliotekanauki.pl/articles/747481.pdf
    Data publikacji:
    2018
    Wydawca:
    Polskie Towarzystwo Matematyczne
    Tematy:
    stochastic gene switching, pharmacodynamics, metronomics therapy
    stochastyczne przełaczanie genów, farmakodynamika, terapie me- tronomiczne
    Opis:
    W niniejszej pracy przedstawiam wstepne wyniki badania wzajemnych oddziaływan stochastycznego przełaczania genów i pewnych terapii metronomicznych. W trakcie badan przeanalizowano odpowiedz prostego modelu genmRNA - białko na zastosowane terapie metronomiczne. Wyniki wskazuja, ze stochastyczne przełaczanie genów, w szczególnosci czas pomiedzy kolejnymi przełaczeniami od-grywa znaczaca role w okresleniu wielkosci frakcji komórek odpowiadajacych na zastosowana terapie.
    In this work I present some preliminary results of the exploration of the interplay between stochastic gene switching and certain metronomics therapies. During the research a simple model of gene-mRNA-protein network subjected to the metronomic therapy was investigated. The results show that the stochastic gene switching process, especially the time expected between successive switching plays a significant role in determining the size of the responding cells fraction.
    Źródło:
    Mathematica Applicanda; 2018, 46, 1
    1730-2668
    2299-4009
    Pojawia się w:
    Mathematica Applicanda
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Polymorphic variants of MIF gene and prognosis in steroid therapy in children with idiopathic nephrotic syndrome
    Autorzy:
    Świerczewska, Monika
    Ostalska-Nowicka, Danuta
    Kempisty, Bartosz
    Szczepankiewicz, Aleksandra
    Nowicki, Michał
    Powiązania:
    https://bibliotekanauki.pl/articles/1039333.pdf
    Data publikacji:
    2014
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    nephrotic syndrome
    steroid resistance
    MIF gene
    single nucleotide polymorphism
    short tandem repeat
    Opis:
    Nephrotic syndrome (NS) is the most common reason of proteinuria in children and can be caused by the pathology of renal glomeruli. Steroid therapy is typically used in this disorder. It has been shown that MIF is a cytokine which counteracts the immunosuppressive properties of glucocorticoids. The aim of this study was looking for a correlation between MIF polymorphisms and genetic susceptibility to steroid resistance in children with INS (Idiopathic NS). Methods: The study was performed in 71 patients with INS including SRNS (steroid resistance nephrotic syndrome) (41) and SSNS (steroid sensitive nephrotic syndrome) (30) and in 30 control subjects. We employed Sanger sequencing and capillary electrophoresis. Linkage disequilibrium was made using Haploview and PHASE. Results: We didn't observe a statistical significance between SNPs detected in patients with INS and controls. Our studies revealed statistical significance for two polymorphisms: rs2070767C > T and rs2000466T > G between patients with SRNS and SSNS. The results for rs34383331T > A are close to being statistically significant. Statistical significance was revealed for CATT5/CATT6 genotype in SRNS group vs SSNS group (OR=4.604, 95%CI=1.356-15.632, p=0.0168). We found that the frequency of 5/X-CATT genotype compared with X/X-CATT genotype was significantly higher in SRNS patients vs SSNS (OR=3.167, 95%CI=1.046-9.585, p=0.0426). In linkage disequilibrium analysis we didn't show involvement in susceptibility to INS and steroid sensitive phenotype. Conclusions: Our results suggest that the role of MIF polymorphisms in the susceptibility to positive response to steroid therapy is still unresolved. It indicates that MIF may be involved in indirect and complex molecular mechanisms of steroid activity in hormone-dependent metabolic pathways in children with INS. Because of ambiguous findings, pleiotropic features of this cytokine require that more research should be undertaken.
    Źródło:
    Acta Biochimica Polonica; 2014, 61, 1; 67-75
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Wykorzystanie grafenu w medycynie : studium literaturowe
    Use of graphene in medicine : the study of literature
    Autorzy:
    Bojko, Ł.
    Ryniewicz, A. M.
    Powiązania:
    https://bibliotekanauki.pl/articles/135964.pdf
    Data publikacji:
    2015
    Wydawca:
    Wyższa Szkoła Techniczno-Ekonomiczna w Szczecinie
    Tematy:
    podawanie leków
    podawanie genów
    nanoplatformy
    terapia nowotworów
    skafoldy
    drug delivery
    gene delivery
    nanoplatforms
    cancer therapy
    scaffolds
    Opis:
    Wstęp i cele: Wyizolowanie warstwy grafenu przez Andre Geim i Kostya Novoselov nastąpiło w 2004 roku. Ze względu na specyficzne właściwości elektryczne, optyczne, chemiczne i mechaniczne grafen znalazł zastosowanie w wielu dziedzinach, w tym w medycynie. Opracowanie poświęcone jest podsumowaniu najnowszych osiągnięć wykorzystania grafenu w procesie dostarczania leków, wykrywania i obrazowania struktur tkankowych, komórkowych i genowych, w tym terapii nowotworów oraz jako materiał w inżynierii tkankowej. Materiał i metody: Materiałem jest literatura dotycząca zagadnień zastosowania grafenu w medycynie. Zastosowano metodę analizy merytorycznej. Wyniki: Analiza literatury pokazuje, że przeszkodami dla biomedycznych zastosowań nanomateriałów na bazie grafenu jest brak biodegradacji i możliwość wystąpienia toksyczności długoterminowej, a obecne badania nie dostarczają pełnej wiedzy w zakresie oddziaływania in vivo nanomateriałów na bazie grafenu, o różnej strukturze, wielkości i właściwości powierzchni. Wniosek: Efektywność kierowania markerów do guzów nowotworowych jest jednym z kluczowych wyzwań biomedycznych dotyczących nie tylko materiałów na bazie grafenu, ale także większości innych nanomateriałów.
    Introduction and aims: The isolation of graphene layers by Andre Geim and Kostya Novoselov was in 2004. Due to the specific properties of the electrical, optical, chemical and mechanical properties, graphene has been applied in many fields, including medicine. Study is devoted to the summary of the latest achievements in the use of graphene to drug delivery, sensing and imaging tissue, cellular, and gene structures, including cancer therapy and as a material for tissue engineering. Material and methods: The material is literature on the issues of application of graphene in medicine. The method of theoretical analysis. Results: Analysis of the literature shows that obstacles to biomedical applications of nanomaterials based on graphene is the lack of biodegradability and the possibility of long-term toxicity and current research does not provide the full knowledge of the interactions in vivo graphene-based nanomaterials, with a different structure, size and surface properties. Conclusion: Efficiency of targeting cancerous tumors markers is one of the key challenges regarding not only the biomedical materials based on graphene, but also most other nanomaterials.
    Źródło:
    Problemy Nauk Stosowanych; 2015, 3; 147-156
    2300-6110
    Pojawia się w:
    Problemy Nauk Stosowanych
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Search for mouse gene related to GA733 human tumor antigen gene
    Autorzy:
    Zielewicz, J
    Skrzypczak, M.
    Wojcierowski, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/2048195.pdf
    Data publikacji:
    1995
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    human antigen
    glycoprotein
    human genetics
    mice
    gene sequence
    adenocarcinoma
    cancer therapy
    electrophoresis
    carcinoma cell
    bacteriophage
    antigen
    gene
    mouse
    oncoantigen
    hybridization
    tumour etiology
    tumour
    DNA
    Opis:
    Human antigen GA733-1, defined as 40 kDa cell glycoprotein, is one of the antigens associated with gastrointestinal carcinomas. Its studies may contribute to the tumor etiology and therapy effects in animal model.
    Źródło:
    Journal of Applied Genetics; 1995, 36, 3; 273-277
    1234-1983
    Pojawia się w:
    Journal of Applied Genetics
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
    Autorzy:
    Bargiel, J.B.
    Cabaj, J.
    Chmielewska, I.
    Milanowski, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/2098542.pdf
    Data publikacji:
    2021
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    non-small cell lung cancer
    crizotinib
    therapy
    gene rearrangement
    tyrosine kinase inhibitor
    patient
    Opis:
    Introduction. Currently, nearly 23,000 cases of lung cancer are diagnosed in Poland annually, of which 5% are cases with rearrangements in the ALK gene. In recent years, tremendous progress has been made in understanding the genetic makeup of this type of cancer, which has enabled the use of new therapies, in particular, molecularly targeted drugs. Crizotinib is the first oral small molecule inhibitor of ALK, MET and ROS1 receptor tyrosine Kinases approved by the European Medicines Agency(EMA). Case report. The paper presents the case of a 62-year-old patient diagnosed with non-small cell lung cancer with rearrangement in the ALK gene in stage IV of the disease. The patient was qualified for treatment with crizotinib under the B6 drug programme. Treatment started in May 2019. During treatment, assessment was made at 3 control points, where the first and second showed a partial response according to the RECIST 1.1 scale; in the next assessment, the response was maintained in the form of disease stabilization.
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2021, 15, 3; 151-154
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    DNA microarrays - future in oncology research and therapy
    Autorzy:
    Krol, M.
    Pawlowski, K.M.
    Otrebska, D.
    Motyl, T.
    Powiązania:
    https://bibliotekanauki.pl/articles/3349.pdf
    Data publikacji:
    2008
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    DNA microarray
    future
    oncology
    research
    therapy
    genomics
    gene expression
    canine mammary cancer
    tumour
    human disease
    cancer
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2008, 02, 2
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The role of macronutrient intake in reducing the risk of obesity and overweight among carriers of different polymorphisms of FTO gene. A review
    Autorzy:
    Przeliorz-Pyszczek, A.
    Regulska-Ilow, B.
    Powiązania:
    https://bibliotekanauki.pl/articles/875573.pdf
    Data publikacji:
    2017
    Wydawca:
    Narodowy Instytut Zdrowia Publicznego. Państwowy Zakład Higieny
    Tematy:
    macronutrient
    human nutrition
    intake
    reducing
    disease risk
    obesity
    overweight
    polymorphism
    FTO gene
    gene expression
    genetic factor
    human diet
    diet therapy
    Opis:
    Obesity is a growing problem worldwide. The risk of the excessive body weight occurrence is a multifactorial issue. Environmental factors, lifestyle habits, diet, physical activity level, as well as genetic predisposition can increase obesity risk. One of the genes studied – the FTO gene - plays a crucial role in obesity occurrence. Individuals who carry risk alleles of specific single nucleotide polymorphisms (SNP) have a greater risk of being overweight. Recent studies revealed that specific macronutrient diet composition can influence differently on the FTO expression. The aim of this article is to review the recent literature on the topic of the FTO gene, its influence on overweight and obesity prevalence and the role of diet in modifying its impact on the risk of the excessive body weight occurrence. There are not many studies focusing on the dietary intervention influence on the FTO gene expression. As far as it has been researched it seems that the proper dietary habits can modify the FTO gene risk allele influence on obesity susceptibility.
    Otyłość jest rosnącym problemem na całym świecie. Ryzyko występowania nadmiernej masy ciała stanowi problem wieloczynnikowy. Czynniki środowiskowe, styl życia, dieta, poziom aktywności fizycznej, a także predyspozycje genetyczne mogą zwiększać ryzyko otyłości. Jeden z badanych genów - gen FTO - odgrywa kluczową rolę w występowaniu otyłości. Osoby, które są nosicielami alleli ryzyka specyficznych polimorfizmów pojedynczych nukleotydów (ang. SNP - Single Nucleotide Polymorphism) tego genu charakteryzują się większym ryzykiem wystąpienia nadwagi. Najnowsze badania wykazały, że specyficzny udział makroskładników diety może wpływać w różny sposób na ekspresję FTO. Celem niniejszego artykułu jest przegląd najnowszej literatury na temat genu FTO, jego wpływ na częstość występowania nadwagi i otyłości oraz roli diety w modyfikacji jego wpływu na ryzyko wystąpienia nadmiernej masy ciała. Niewiele jest badań dotyczących wpływu interwencji dietetycznych na ekspresję genu FTO. Tak dalece jak to zostało zbadane wydaje się, że odpowiednie nawyki żywieniowe mogą modyfikować wpływ alleli genu FTO na ryzyko wystąpienia otyłości.
    Źródło:
    Roczniki Państwowego Zakładu Higieny; 2017, 68, 1
    0035-7715
    Pojawia się w:
    Roczniki Państwowego Zakładu Higieny
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Detection of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutant gene amongst malaria-infected pregnant women in Calabar, Nigeria
    Autorzy:
    Monjol, Bernard Ekpan
    Useh, Monday Francis
    Powiązania:
    https://bibliotekanauki.pl/articles/972121.pdf
    Data publikacji:
    2017
    Wydawca:
    Polskie Towarzystwo Parazytologiczne
    Tematy:
    malaria
    chloroquine
    artemisinin-based combination therapy
    microscopy
    PCR
    PFCRT
    Opis:
    Chemotherapy is the mainstay in malaria control and management. For some time, chloroquine (CQ) was a drug of choice for the treatment of malaria. It was effective against all forms of malaria, cheap and readily available. The increased resistance of malaria parasites to CQ led to widespread abandonment of the drug in African and Asian countries on the prompting of the World Health Organization. Currently, artemisinin-based combination therapy is the gold standard for the treatment of malaria. This study investigates the presence of the Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT) mutant gene, a molecular marker responsible for CQ resistance in malaria parasites. A total of 369 pregnant women were microscopically screened for malaria infection using thin and thick blood films stained with Giemsa. Subsequently, malaria parasite DNA was extracted from the blood of malaria positive participants. The PfCRT gene was amplified using Polymerase Chain Reaction (PCR). A Restriction Fragment Length Polymorphism analysis of the gene was performed to confirm mutant forms. The results showed that 251 (68.0%) of the participants had Plasmodium falciparum in their blood. Molecular examination revealed the presence of PfCRT mutant genes in 28% of the study population. Notwithstanding the decline in the prevalence of PfCRT T76 mutation since the antimalarial policy change in Nigeria, the 28% prevalence recorded in this study is considered high after ten years of the withdrawal of CQ in the treatment of uncomplicated malaria.
    Źródło:
    Annals of Parasitology; 2017, 63, 4; 323-330
    0043-5163
    Pojawia się w:
    Annals of Parasitology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Expression of genes modulated by epigallocatechin-3-gallate in breast cancer cells
    Autorzy:
    Bogacz, A.
    Wolek, M.
    Juskowiak, B.
    Karasiewicz, M.
    Kaminski, A.
    Uzar, I.
    Polaszewska, A.
    Kostrzewa, Z.
    Czerny, B.
    Powiązania:
    https://bibliotekanauki.pl/articles/72469.pdf
    Data publikacji:
    2018
    Wydawca:
    Instytut Włókien Naturalnych i Roślin Zielarskich
    Tematy:
    gene expression
    epigallocatechin-3-gallate
    breast cancer
    cancer cell
    therapy
    Opis:
    Breast cancer is the most common malignant cancer among women. Both drug resistance and metastasis are major problems in the treatment of breast cancer. Therefore, adjuvant therapy may improve patients’ survival and affect their quality of life. It is suggested that epigallocatechin gallate (EGCG) which is well known for its chemopreventive activity and acts on numerous molecular targets may inhibit the growth and metastasis of some cancers. Hence, discovering the metastatic molecular mechanisms for breast cancer may be useful for therapy.The aim of the study was to determine the effect of EGGC on the mRNA expression level of genes such as ZEB1, ABCB1, MDM2, TWIST1 and PTEN in MCF-7 breast cancer cells. MCF7/DOX were cultured in the presence of 0.2 μM DOX and EGCG (20-50 μM). The mRNA expression level was determined by real-time quantitative PCR using RealTime ready Custom Panel 96 kit. Our results showed an important increase (about 2-fold for 20 μM EGCG + 0.2 μM DOX and 2.5-fold for 50 μM EGCG + 0.2 μM DOX, p<0.05) in ZEB1 expression levels. In case of ABCB1 gene lack of influence on the mRNA level was observed (p>0.05). We also observed significant decrease of ZEB1 expression in MCF7 cells with 20 μM and 50 μM EGCG (p<0.05). In addition, EGCG (20 μM) caused an increase of MDM2 and PTEN mRNA levels in almost 100% (p<0.05) and 40% (p>0.05), respectively. Lack of the influence of EGCG was noted for the TWIST1 gene expression. In case of MCF7/DOX we showed an increase of mRNA level of PTEN gene about 50% (p<0.05). These results suggest that EGCG may be potentially used in adjuvant therapy in the breast cancer treatment.
    Źródło:
    Herba Polonica; 2018, 64, 3
    0018-0599
    Pojawia się w:
    Herba Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Czy „cichy” polimorfizm pojedynczego nukleotydu (SNP) C1236T genu ABCB1 jest związany z predyspozycją do rozwoju depresji i skutecznością jej leczenia? - badanie wstępne
    Is the „silent” single nucleotide polymorphism (SNP) C1236T of ABCB1 gene associated with predisposition to depression development and efficiency of therapy? – preliminary study
    Autorzy:
    Jeleń, Agnieszka
    Koziróg, Anna
    Sałagacka, Aleksandra
    Balcerczak, Ewa
    Talarowska, Monika
    Gałecki, Piotr
    Powiązania:
    https://bibliotekanauki.pl/articles/1032546.pdf
    Data publikacji:
    2014
    Wydawca:
    Łódzkie Towarzystwo Naukowe
    Tematy:
    abcb1
    polimorfizm pojedynczego nukleotydu
    c1236t
    glikoproteina p
    depresja
    farmakogenomika
    podatność
    single nucleotide polymorphism
    p-glycoprotein
    depression
    pharmacogenomics
    susceptibility
    Opis:
    Introduction: According to the World Health Organization about 350 million people around the world are affected by depression. Despite the high prevalence of this disease the mechanism of depression origination as well as the causes of the resistance to therapy are still not fully understood. ABCB1 gene encode P glycoprotein which is one of the components of blood-brain barrier. The main function of this protein is the efflux of many toxic compounds, including drugs, which may indicate potential association between the proper functioning of P glycoprotein and the susceptibility to the development of depressive disorders or the failure of antidepressant therapy. The objective of this study was to evaluate single nucleotide polymorphism (SNP) C1236T of the ABCB1 gene in the group of patients with recurrent depressive disorder (rDD) and to estimate the possible association of this polymorphism with the response to antidepressant therapy. Material and methods: C1236T was evaluated in 30 patients with rDD. Genotyping was performed using automated sequencing (the Sanger method). The results were compared with those obtained from the control group which consisted of 96 blood donors from the local blood bank. Results: No statistically significant difference in the frequency of genotypes (p=0.0665) and allele (p=0.1489) for the SNP C1236T of ABCB1 gene was found between the patients with rDD and the control group. No correlation between C1236 and the age when the disease was stated (p=0.0807). Neither the association between genotypes and the severity of depressive symptoms before treatment (p=0.7956) nor the association with effectiveness of the therapy (p=0.2051) were found. Conclusions: On the basis of the results of the preliminary study, C1236T of ABCB1 gene have no influence on the predisposition to rDD, the severity of depressive symptoms and the efficiency of antidepressant therapy have not been stated, either.
    Streszczenie Wstęp: Według danych Światowej Organizacji Zdrowia depresja dotyka około 350 milionów osób na całym świecie. Jednak pomimo powszechnego występowania, zarówno etiologia tej choroby, jak i przyczyny oporności na leczenie w dalszym ciągu nie są w pełni poznane. Gen ABCB1 koduje glikoproteinę P, która jest jednym z elementów bariery krew-mózg. Główną funkcją białka jest usuwanie związków toksycznych, w tym także leków, co może wskazywać na potencjalny związek między prawidłowym działaniem glikoproteiny P a predyspozycją do rozwoju zaburzeń depresyjnych czy niepowodzeniem terapii lekami przeciwdepresyjnymi. Celem pracy była ocena polimorfizmu pojedynczego nukleotydu (ang. single nucleotide polymorphism - SNP) C1236T genu ABCB1 wśród chorych na zaburzenia depresyjne nawracające (ang. recurrent depressive disorder - rDD) oraz oszacowanie potencjalnego związku tego polimorfizmu z odpowiedzią na terapię lekami przeciwdepresyjnymi. Materiał i metody: Polimorfizm C1236T oceniono w grupie 30 pacjentów, u których zdiagnozowano rDD. Genotyp określono wykorzystując technikę automatycznego sekwencjonowania metodą Sangera. Otrzymane wyniki porównano z wynikami grupy kontrolnej, którą stanowiło 96 dawców krwi z lokalnego banku krwiodawstwa. Wyniki: Nie stwierdzono istotnych statystycznie różnic w częstości występowania poszczególnych genotypów (p=0,0665) i alleli (p=0,1489) polimorfizmu C1236T genu ABCB1 między grupą pacjentów z rDD a grupą kontrolną. Nie wykazano również zależności pomiędzy C1236T a wiekiem w chwili diagnozy rDD (p=0,0807), nasileniem objawów depresji przed rozpoczęciem terapii (p=0,7956) czy skutecznością leczenia przeciwdepresyjnego (p=0,2051). Wnioski: Na podstawie wyników badania wstępnego, stwierdzono brak wpływu polimorfizmu C1236T genu ABCB1 na predyspozycję do rozwoju rDD, nasilenie objawów depresji w chwili diagnozy czy skuteczność terapii przeciwdepresyjnej.
    Źródło:
    Folia Medica Lodziensia; 2014, 41, 1; 5-15
    0071-6731
    Pojawia się w:
    Folia Medica Lodziensia
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-37 z 37

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies